Bicara Therapeutics BCAX Business Segments — Clinical operations and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept bcax:ManufacturingAndProcessDevelopmentExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — clinical operations and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — clinical operations and development?
- Bicara Therapeutics (BCAX) reported business segments — clinical operations and development of $23.21M in Q1 2026.
- How has Bicara Therapeutics's business segments — clinical operations and development changed year-over-year?
- Bicara Therapeutics's business segments — clinical operations and development increased by 24.4% year-over-year, from $18.66M to $23.21M.
- What is the long-term trend for Bicara Therapeutics's business segments — clinical operations and development?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — clinical operations and development has grown at a 103.1% compound annual growth rate (CAGR), from $11.84M to $48.8M.
- What does business segments — clinical operations and development mean?
- Represents the direct costs associated with conducting clinical trials and managing the development pipeline for therapeutic candidates. This includes expenses related to patient enrollment, clinical site management, and regulatory compliance activities necessary to advance drug candidates through clinical phases.